延迟1个月使用甲氨蝶呤对早期类风湿关节炎患者肺炎球菌疫苗免疫原性与疾病控制的影响(VACIMRA):一项开放标签随机试验
这项在法国26个风湿科进行的开放标签随机试验纳入249例早期活动性类风湿关节炎患者,比较甲氨蝶呤与PCV13疫苗同时开始(即刻组)或PCV13后1个月开始甲氨蝶呤(延迟组)的体液应答。延迟组对至少3个目标血清型的应答率更高(IgG相对风险1.46,95%CI 1.10-1.92,p=0.02;调理吞噬试验1.65,95%CI 1.25-2.19,p=0.01),且1年内疾病活动度无显著影响。
要点
- 延迟组1个月时PCV13应答率高于即刻组:IgG相对风险1.46(95%CI 1.10-1.92,p=0.02)。
- 延迟组调理吞噬试验应答相对风险1.65(95%CI 1.25-2.19,p=0.01)。
- 12个月时延迟组13个血清型中8个抗体功能活性显著更高,疾病活动度组间相当。
核心结论
- 在早期类风湿关节炎患者中,甲氨蝶呤开始前1个月接种PCV13疫苗可改善免疫应答,且1年随访期间对疾病控制无显著影响。
- 未来步骤是用PCV20或PCV21确认这些结果,并评估加强疫苗的最佳时间窗。
研究设计与样本
- 随机、多中心、开放标签试验,从法国22所大学医院和4所综合医院的26个风湿科招募患者。
- 纳入18-80岁、DAS28>3.2、未用过靶向DMARD、近3个月未用甲氨蝶呤或来氟米特、无既往肺炎球菌疫苗接种史的活动性类风湿关节炎患者。
- 患者随机化时接种PCV13,随后按1:1随机分为即刻组(甲氨蝶呤最大剂量15 mg/周与PCV13同时开始)或延迟组(PCV13后1个月开始甲氨蝶呤),随机化按性别和自我报告的DMARD初治状态分层。
- 2个月后两组均接种23价肺炎球菌多糖疫苗。
- 主要分析在改良意向治疗人群中进行,共249例(延迟组126例[51%],即刻组123例[49%])。
主要发现
- 2013年9月27日至2019年10月10日共随机分配276例患者,27例被排除(其中4例退出),249例纳入改良意向治疗人群。
- 174例(70%)为女性,75例(30%)为男性,入组时平均年龄55.6岁(SD 14.8)。
- 延迟组相比即刻组,IgG应答率相对风险1.46(95%CI 1.10-1.92;p=0.02),调理吞噬试验应答相对风险1.65(95%CI 1.25-2.19;p=0.01),均经性别和真实DMARD初治状态校正。
- 12个月时,延迟组13个血清型中8个的抗体功能活性显著更高。
- 两组间累积糖皮质激素剂量和接受靶向DMARD的患者数全程相似;649例不良事件中72例(11%)为严重不良事件(包括1例疫苗相关严重不良事件),两组发生率相当;随访期间DAS28保持可比。
关键数值与推荐
- 主要结局为1个月时应答率,定义为对5个目标血清型(1、3、5、7F和19A)中至少3个产生阳性应答。
- 应答者定义为与基线相比,ELISA或调理吞噬试验测定的IgG浓度增加2倍或以上。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来步骤是用PCV20或PCV21确认这些结果,并评估加强疫苗的最佳时间窗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal vaccination is recommended for patients with rheumatoid arthritis. Because immunosuppressant therapies for rheumatoid arthritis hinder vaccine efficacy, vaccination should be administered before initiating immunosuppressive drugs. We aimed to compare humoral responses in patients with rheumatoid arthritis receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before methotrexate initiation or simultaneously. METHODS: In this randomised, multicentre, open-label trial, patients were recruited from 26 rheumatology departments in 22 university hospitals and four general hospitals in France. Adult patients (aged 18-80 years) with active rheumatoid arthritis (Disease Activity Score in 28 joints >3·2), who were naive to targeted disease-modifying anti rheumatic drugs (DMARDs), had not had methotrexate or leflunomide in the past 3 months, and had no previous pneumococcal vaccinations were included. Patients were excluded in case of treatment with methotrexate or with leflunomide within the previous 3 months and absolute or relative contraindications to methotrexate. Patients were vaccinated with PCV13 at randomisation, before being randomly assigned (1:1) to either the immediate group (methotrexate treatment [maximum dose 15 mg per week] initiated at the same time as PCV13 vaccine) or the delay group (methotrexate initiated 1 month after PCV13 vaccine). Randomisation was stratified by sex (self-reported) and DMARD naive status. 2 months later, patients in both groups were vaccinated with the 23-valent pneumococcal polysaccharide vaccine. Humoral responses, disease activity, infections, and adverse events were assessed at baseline and at 1, 3, 6, and 12 months after PCV13. The primary outcome was the responder rate at 1 month, defined by positive responses against at least three of five target serotypes (ie, 1, 3, 5, 7F, and 19A). Responders were defined according to a 2 or more-fold increase in IgG concentrations with ELISA or opsonophagocytic assay compared with baseline. The main analysis was performed in the modified intention-to-treat population, including all randomly assigned patients with a valid measure of the primary endpoint, analysed in their assigned group. There was no involvement of people with lived experience in the study design or implementation. The trial was registered at ClinicalTrials.gov (NCT01942174) and is completed. FINDINGS: Between Sept 27, 2013, and Oct 10, 2019, 276 patients with rheumatoid arthritis were randomly assigned. 27 patients were excluded, of whom four patients dropped out, and 249 patients were included in the modified intention-to-treat population (126 [51%] in the delay group and 123 [49%] in the immediate group). 174 (70%) patients were female and 75 (30%) were male, the mean age at enrolment was 55·6 years (SD 14·8). Responder rates were higher in the delay group compared with the immediate group for IgG concentrations (relative risk 1·46 [95% CI 1·10-1·92]; p=0·02) and for opsonophagocytic assay activity (1·65 [1·25-2·19]; p=0·01), adjusted for sex and true DMARD naive status. At 12 months, antibody functional activity was significantly higher for eight of 13 serotypes in the delay group. Cumulative doses of corticosteroids and the number of patients who had targeted DMARDs were similar between groups throughout. 72 (11%) of 649 adverse events were serious (including one vaccine-related serious adverse event) in both groups and were equally frequent between groups, and the rheumatoid arthritis disease activity score remained comparable during follow-up. INTERPRETATION: In patients with early rheumatoid arthritis, the PCV13 vaccine administered 1 month before methotrexate allowed for improved immunological responses without significant effect on disease control during one year of follow-up. Future steps are to confirm these results with PCV20 or PCV21 and assess the best time frame for the booster vaccine. FUNDING: Government of France and Pfizer. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
引用
- Morel J, Dernis E, Roux C, et al. Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial. Lancet Rheumatol. 2025. PMID: 40749694. doi:10.1016/S2665-9913(25)00071-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。